ProShare Advisors LLC Has $24.01 Million Position in Pfizer Inc. (NYSE:PFE)

ProShare Advisors LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 15.0% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 904,859 shares of the biopharmaceutical company's stock after buying an additional 118,216 shares during the period. ProShare Advisors LLC's holdings in Pfizer were worth $24,006,000 as of its most recent filing with the SEC.

A number of other large investors have also made changes to their positions in the stock. Retirement Wealth Solutions LLC acquired a new position in Pfizer in the fourth quarter worth about $26,000. Rialto Wealth Management LLC acquired a new position in Pfizer in the fourth quarter worth about $26,000. Clarity Asset Management Inc. acquired a new position in Pfizer in the fourth quarter worth about $27,000. Kohmann Bosshard Financial Services LLC acquired a new position in Pfizer in the fourth quarter worth about $28,000. Finally, Noble Wealth Management PBC acquired a new position in Pfizer in the fourth quarter worth about $31,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Analyst Ratings Changes

Several research firms recently issued reports on PFE. Hsbc Global Res raised shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Cantor Fitzgerald started coverage on shares of Pfizer in a report on Tuesday, April 22nd. They set a "neutral" rating and a $24.00 price objective for the company. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $25.00 price objective (down previously from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Guggenheim reaffirmed a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. Finally, UBS Group raised their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $29.17.

Pfizer Price Performance

PFE opened at $22.83 on Friday. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The company's 50 day simple moving average is $23.65 and its 200-day simple moving average is $25.36. The stock has a market capitalization of $129.77 billion, a P/E ratio of 16.19, a price-to-earnings-growth ratio of 0.64 and a beta of 0.58.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 EPS for the quarter, beating the consensus estimate of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same period in the prior year, the firm earned $0.82 earnings per share. Pfizer's revenue was down 7.8% compared to the same quarter last year. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.54%. Pfizer's payout ratio is presently 124.64%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.